A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Research at City of Hope reveals how common white button mushrooms might enhance prostate cancer treatment through surprising ...

John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.